Geographical Expansion
Expected: OngoingHIGH confidence
What: Export Revenue %: 62%
“our dedicated sales team is now fully operational, and we have started securing both regulatory and customer approvals.”
Sudeep Pharma Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +21.4%Average4w StreakRe-Entry
In , Sudeep Pharma Ltd (Pharmaceuticals Bulk Drugs & Formulation) is outperforming Nifty 500 with +21.4% relative strength. Fundamentals: Average. On a 4-week streak.
Sudeep Pharma Ltd Key Facts
- PE Ratio
- 52.9x
- Market Cap
- ₹9,140 Cr
- PAT Growth YoY
- +11%
- Revenue Growth YoY
- +15%
- OPM
- 34.0%
- RS vs Nifty 500
- +21.4%
What's Happening
💰Trading 30% above estimated fair value — significant premium
Earnings Acceleration Triggers
1. Geographical Expansion
OngoingHIGH
2. New Product Or Brand Launch
H2 FY27HIGH
3. Value Added Product Mix Shift
OngoingMEDIUM
Key Risks
1. 50% of US business was subject to tariffs, causing a wait-and-watch approach by
MEDIUM2. China's elimination of VAT rebates on exports could increase global prices for c
LOW3. Need for localized stocking to improve service levels in US and Europe
LOWSector-Specific Signals
Export Revenue % of Total62%+100 bps
Specialty Ingredients Revenue %41%
Pharma/Food Vertical Utilization65-70%
Specialty Vertical Utilization40%
Key Numbers
PAT Growth YoY
+11%
Inflection Up
Revenue YoY
+15%
Stable
Operating Margin
34.0%
-300 bps YoY
PE Ratio
52.9
Current Price
₹809
Fundamental Score
46/100
Average
3Y PAT CAGR
+14%
Market Cap
9.1K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Sudeep Pharma Ltd's Earnings Accelerating?
Based on Q3 FY26 earnings • Updated Apr 19, 2026
New Product Or Brand Launch
Expected: H2 FY27HIGH confidence
What: New Capacity: 51,200 MT
Impact: 3x asset turn
“This facility will enable industrial-scale production of higher-value molecules such as gluconates, glycinates and citrines.”
Value Added Product Mix Shift
Expected: OngoingMEDIUM confidence
What: Specialty Revenue %: 41%
“While our core minerals provide resilience, it is the specialty ingredient segment that is increasingly driving incremental value”
Regulatory Approval Or License Win
Expected: OngoingMEDIUM confidence
What: CEP Certification: 1 of 9 globally
“In Europe, our CEP certification for calcium carbonate... significantly reduces entry barriers and accelerates product approvals.”
Operating Leverage Inflection
Expected: FY27-28LOW confidence
What: Utilization %: 35-40% in Specialty
“The specialty ingredients vertical... we are probably at close to 35% to 40% utilization.”
Revenue growth of 52% YoY
HIGH confidence
What: Revenue growth of 52% YoY
“Total income for the quarter grew by 52% on year-on-year basis to INR179.2 crores in Q3 FY '26 as compared to INR118 crores”
SAM Capex guidance raised
HIGH confidence
What: ₹220 Cr for Phase 1 → ₹300 Cr for Phase 1
“Phase 1 capex of approximately INR300 crores, which includes the land for the entire 100,000 ton facility.”
What Are the Key Risks for Sudeep Pharma Ltd?
Earnings deceleration risks from management commentary
50% of US business was subject to tariffs, causing a wait-and-watch approach by
MEDIUMTrigger: US tariff announcements in August 2025 led to measured procurement cycles.
Management view: Passed on tariff impact to 90% of affected customers; 50% of business is now exempt.
Monitor: regulatory
China's elimination of VAT rebates on exports could increase global prices for c
LOWTrigger: Recent policy changes in China affecting Di-calcium phosphate and battery chemicals.
Management view: Supports the narrative for an ex-China supply chain; Sudeep is well-positioned as an alternative.
Monitor: geopolitical
Need for localized stocking to improve service levels in US and Europe
LOWTrigger: Expanding global business base requires warehousing to ensure responsiveness.
Management view: Commenced warehousing operations in USA and Europe.
Monitor: logistics
What Is Sudeep Pharma Ltd's Management Saying?
Key quotes from recent conference calls
“I think, if you see our business is delivered above 35% for the past couple of years and then we expect to maintain that going forward as well. [Previous EBITDA Margin guidance]”
“the company expects its working capital cycle to moderate and sustain approximately around 140 to 150 days over the medium term. [Previous Working Capital Cycle guidance]”
“Phase 1 capacity of 25,000 metric tons per annum remains on track for commissioning in early 2027. [Initiative: Dahej Battery Materials Facility]”
“This facility will enable industrial-scale production of higher-value molecules such as gluconates, glycinates and citrines. [Initiative: Nandesari Greenfield Expansion]”
What Did Sudeep Pharma Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹179.2 Cr
YoY +52%QoQ +3.7%
Why: Growth was driven by better demand and deeper customer engagement across regions, particularly in Asia-Pacific and India.
Revenue growth accelerated significantly from the 15% YoY growth reported in Q2.
EBITDA
₹66.8 Cr
YoY +60%Margin 37.3%
Why: EBITDA growth outpaced revenue due to operating leverage and a favorable product mix, despite ongoing investments in sales teams.
Margins remained stable within the historical 35-37% range despite the scale-up of the specialty business.
PAT
₹47.7 Cr
YoY +66%QoQ +1.9%
Why: PAT growth was supported by strong operational performance and the integration of the NSS acquisition.
PAT margins improved to 26.6% from 24.3% in the same quarter last year.
Other Highlights
• Export business contributed 62% of total revenue in Q3 FY26.
• Specialty business contributed 41% of Q3 revenue vs 40% in H1.
• Domestic market in India delivered growth of nearly 20% during the quarter.
What Sector Metrics Matter for Sudeep Pharma Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Export Revenue % of Total
62%
YoY +100 bpsQoQ +100 bps
Why: Driven by the operationalization of direct sales teams in Europe and the US.
Specialty Ingredients Revenue %
41%
QoQ +100 bps
Why: Increased traction in encapsulated and premixed product lines for food applications.
Pharma/Food Vertical Utilization
65-70%
QoQ 0%
Why: Operating close to optimum levels, necessitating the new Greenfield expansion.
Specialty Vertical Utilization
40%
QoQ +500 bps
Why: Ramping up after the facility was commissioned in 2022; many customer approvals received this quarter.
Nandesari Greenfield Capacity
51,200 MT
QoQ 0
Why: On track for commissioning in March 2026 to address rising demand.
Dahej Phase 1 Battery Capacity
25,000 MT
QoQ 0
Why: Ground broken in January 2026; targeted for early 2027 completion.
R&D as % of Revenue
2%
YoY 0%QoQ 0%
Why: Consistent investment to maintain innovation pipeline of 200+ projects.
Networking Capital Cycle
180 days
QoQ -15 days
Why: Moderating from 195 days in Q2 but still high due to international inventory building.
Battery Material Customer Count
34
QoQ 0
Why: Engaged across the value chain with 70% approval rate on samples.
NSS Quarterly Revenue
₹17 Cr
QoQ -₹3 Cr
Why: Slightly lower than Q2's ₹20 Cr due to campaign-based ordering patterns.
What Is Sudeep Pharma Ltd's Management Guidance?
Forward-looking targets from management for FY26
Revenue Growth Target
26%
OPM Guidance
35–37%
Capex Plan
₹600 Cr
Revenue Outlook
26% for the full year
Margin Outlook
Maintain historical margin levels
Capex Plan
₹550-600 Cr
Total project cost for 1 lakh tons of battery material capacity
Management Tone: BULLISH
Guidance Changes
RAISED
SAM Capex: ₹220 Cr for Phase 1 → ₹300 Cr for Phase 1
How Fast Is Sudeep Pharma Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +15% | +18% | Stable |
| PAT (Net Profit) | +11% | +14% | Inflection Up |
| OPM | 34.0% | -300 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 19, 2026.
Other Top Pharmaceuticals Bulk Drugs & Formulation Stocks Beating Nifty 500
Frequently Asked Questions: Sudeep Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Sudeep Pharma Ltd's latest quarterly results?
Sudeep Pharma Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +11.4% (turning around (inflection up))
- Revenue Growth YoY: +15.2%
- Operating Margin: 34.0% (volatile)
Is Sudeep Pharma Ltd's profit growing or declining?
Sudeep Pharma Ltd's profit is growing with an turning around (inflection up) trend.
- PAT Growth YoY: +11.4% (latest quarter)
- PAT Growth QoQ: +2.1% (sequential)
- 3-Year PAT CAGR: +14.4%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Sudeep Pharma Ltd's revenue growth trend?
Sudeep Pharma Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +15.2%
- Revenue Growth QoQ: +5.8% (sequential)
- 3-Year Revenue CAGR: +18.3%
How is Sudeep Pharma Ltd's operating margin trending?
Sudeep Pharma Ltd's operating margin is volatile.
- Current OPM: 34.0%
- OPM Change YoY: -3.0% basis points
- OPM Change QoQ: -1.0% basis points
What is Sudeep Pharma Ltd's 3-year profit and revenue CAGR?
Sudeep Pharma Ltd's long-term compounding rates
- 3-Year Profit CAGR: +14.4%
- 3-Year Revenue CAGR: +18.3%
Is Sudeep Pharma Ltd's growth accelerating or decelerating?
Sudeep Pharma Ltd's earnings growth is turning around (inflection up) with positive momentum on a sequential basis.
- YoY Acceleration: -54.1% bps
- Sequential Acceleration: 0.0% bps
- Margin Warning: Operating margins are under pressure
Is Sudeep Pharma Ltd overvalued or undervalued?
Sudeep Pharma Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 52.9x
- Price-to-Book: 10.3x
What is Sudeep Pharma Ltd's current PE ratio?
Sudeep Pharma Ltd's current PE ratio is 52.9x.
- Current PE: 52.9x
- Market Cap: 9.1K Cr
How does Sudeep Pharma Ltd's valuation compare to its history?
Sudeep Pharma Ltd's current PE is 52.9x.
- Current PE: 52.9x
- Valuation Assessment: Significantly Overvalued
What is Sudeep Pharma Ltd's price-to-book ratio?
Sudeep Pharma Ltd's price-to-book ratio is 10.3x.
- Price-to-Book (P/B): 10.3x
- Book Value per Share: ₹78
- Current Price: ₹809
Is Sudeep Pharma Ltd a fundamentally strong company?
Sudeep Pharma Ltd is rated Average with a fundamental score of 45.92/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +15.2% (10% weight)
- PAT Growth YoY: +11.4% (10% weight)
- PAT Growth QoQ: +2.1% (10% weight)
- Margins stable (10% weight)
Is Sudeep Pharma Ltd debt free?
Sudeep Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹150 Cr
What is Sudeep Pharma Ltd's return on equity (ROE) and ROCE?
Sudeep Pharma Ltd's return ratios over recent years
- FY2025: ROCE 36.0%
- FY2026: ROCE 28.0%
Is Sudeep Pharma Ltd's cash flow positive?
Sudeep Pharma Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹70 Cr
- Free Cash Flow (FCF): ₹-261 Cr
- CFO/PAT Ratio: 40% (weak cash conversion)
What is Sudeep Pharma Ltd's dividend yield?
Sudeep Pharma Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹809
Who holds Sudeep Pharma Ltd shares — promoters, FII, DII?
Sudeep Pharma Ltd's shareholding pattern (Mar 2026)
- Promoters: 76.2%
- FII (Foreign): 1.6%
- DII (Domestic): 18.1%
- Public: 4.2%
Is promoter holding increasing or decreasing in Sudeep Pharma Ltd?
Sudeep Pharma Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 76.2% (Mar 2026)
- Previous Quarter: 76.2% (Dec 2025)
- Change: 0.00% (stable)
How long has Sudeep Pharma Ltd been outperforming Nifty 500?
Sudeep Pharma Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Sudeep Pharma Ltd a new momentum entry or an established outperformer?
Sudeep Pharma Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
What are the growth catalysts for Sudeep Pharma Ltd?
Sudeep Pharma Ltd has 7 key growth catalysts identified from recent earnings analysis
- Geographical Expansion — Direct sales teams in Europe and US are now fully operational and securing approvals.
- New Product Or Brand Launch — New facility will produce high-margin gluconates and glycinates.
- Value Added Product Mix Shift — Specialty ingredients like encapsulated minerals are seeing wider adoption in food segments like tortillas.
- Regulatory Approval Or License Win — CEP certification for calcium carbonate reduces entry barriers in the regulated European market.
What are the key risks in Sudeep Pharma Ltd?
Sudeep Pharma Ltd has 3 key risks worth monitoring
- [MEDIUM] 50% of US business was subject to tariffs, causing a wait-and-watch approach by — US tariff announcements in August 2025 led to measured procurement cycles.
- [LOW] China's elimination of VAT rebates on exports could increase global prices for c — Recent policy changes in China affecting Di-calcium phosphate and battery chemicals.
- [LOW] Need for localized stocking to improve service levels in US and Europe — Expanding global business base requires warehousing to ensure responsiveness.
What did Sudeep Pharma Ltd's management say in the latest earnings call?
In Q3 FY26, Sudeep Pharma Ltd's management highlighted
- "I think, if you see our business is delivered above 35% for the past couple of years and then we expect to maintain that going forward as well. [Prev..."
- "the company expects its working capital cycle to moderate and sustain approximately around 140 to 150 days over the medium term. [Previous Working Ca..."
- "Phase 1 capacity of 25,000 metric tons per annum remains on track for commissioning in early 2027. [Initiative: Dahej Battery Materials Facility]"
What is Sudeep Pharma Ltd's management guidance for growth?
Sudeep Pharma Ltd's management has provided the following forward guidance for FY26
- Revenue growth target: 26%
- OPM guidance: 35–37%
- Capex plan: ₹600 Cr for Total project cost for 1 lakh tons of battery material capacity
- Management tone: bullish
- Milestone: [RAISED] SAM Capex: ₹220 Cr for Phase 1 → ₹300 Cr for Phase 1
What sector-specific metrics matter most for Sudeep Pharma Ltd?
Sudeep Pharma Ltd's most important sub-sector-specific KPIs from the latest concall
- Export Revenue % of Total: 62% (YoY +100 bps) (QoQ +100 bps) — Driven by the operationalization of direct sales teams in Europe and the US.
- Specialty Ingredients Revenue %: 41% (QoQ +100 bps) — Increased traction in encapsulated and premixed product lines for food applications.
- Pharma/Food Vertical Utilization: 65-70% (QoQ 0%) — Operating close to optimum levels, necessitating the new Greenfield expansion.
- Specialty Vertical Utilization: 40% (QoQ +500 bps) — Ramping up after the facility was commissioned in 2022; many customer approvals received this quarter.
- Nandesari Greenfield Capacity: 51,200 MT (QoQ 0) — On track for commissioning in March 2026 to address rising demand.
- Dahej Phase 1 Battery Capacity: 25,000 MT (QoQ 0) — Ground broken in January 2026; targeted for early 2027 completion.
Is Sudeep Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Sudeep Pharma Ltd may be worth studying
- Earnings growing at +11.4% YoY
- Cash flow is positive — CFO ₹70 Cr
What is the investment thesis for Sudeep Pharma Ltd?
Sudeep Pharma Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +15.2% YoY
- Growth catalyst: Geographical Expansion
Risk Factors (Bear Case)
- Margins under pressure
- Appears significantly overvalued
- Key risk: 50% of US business was subject to tariffs, causing a wait-and-watch approach by
What is the future outlook for Sudeep Pharma Ltd?
Sudeep Pharma Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Overvalued
- Key Catalyst: Geographical Expansion
- Key Risk: 50% of US business was subject to tariffs, causing a wait-and-watch approach by
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.